TESARO, Inc. is a publicly traded company as of June 2012.
Below is PrivCo's archived report for TESARO, Inc.
Get Full Access To This Report 
| or | Upgrade to PrivCo Premium |
| $99 Single Company Access | Instant Full Site-Wide Access Currently 50% Off Until May. 31! |
TESARO, Inc. is a privately-held, venture capital backed biotechnology company that specializes in biopharmaceuticals. TESARO, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. The company had its IPO in June 2012.
| Company Tags: | PE Backed VC Backed |
| Year Founded: | 2010 |
| Fiscal Year End: | 12/31 |
| City: | Waltham |
| State/Province: | Massachusetts |
| Country: | United States |
| Phone: | View |
| Website: | www.tesarobio.com |
The PrivCo Industry Classification System™ (PICS) is our proprietary, modernized industry classification system, geared especially toward privately-held companies and including newer emerging sub-industries that are not reflected in other outdated industry classification systems, such as SIC and NAICS.
Export All TESARO, Inc. Financials To Excel
$99 Single Company AccessInstant Full Site-Wide Access| Balance Sheet | 2012 | 2011 | 2010 |
| Current Assets | View | View | View |
| Cash and Cash Equivalents3 | View | View | View |
| Property, Plant and Equipment | View | View | View |
| Total Assets | View | View | View |
| Current Liabilities | View | View | View |
| Accounts Payable | View | View | View |
| Other Current Liabilities | View | View | View |
| Total Liabilities | View | View | View |
| Stockholders Equity | View | View | View |
| Additional Paid-in Capital | View | View | View |
| Retained Earnings | View | View | View |
| Accrued Expenses | View | View | View |
| Total Preferred Equity | View | View | View |
| Total Common Equity | View | View | View |
| Financial Notes: | |
| * | TESARO, Inc. fiscal year end: 12/31 |
| 1 | All 2012 figures... read more. |
| 2 | All 2012 Income... read more. |
| 3 | All 2012 Balance... read more. |
| 4 | All 2012 Cash Flow... read more. |
Export All TESARO, Inc. Financials To Excel
$99 Single Company AccessInstant Full Site-Wide AccessTESARO, Inc. Selling, General & Administrative Expenses ($ MM): |
TESARO, Inc. Research & Development Expense ($ MM): |
TESARO, Inc. Total Operating Expenses ($ MM): |
TESARO, Inc. Operating Income (Loss) ($ MM): |
TESARO, Inc. EBITDA ($ MM): |
TESARO, Inc. Interest Expense ($): |
TESARO, Inc. Net Income (Loss) ($ MM): |
TESARO, Inc. Current Assets ($ MM): |
TESARO, Inc. Cash and Cash Equivalents ($ MM): |
TESARO, Inc. Property, Plant and Equipment ($): |
TESARO, Inc. Total Assets ($ MM): |
TESARO, Inc. Current Liabilities ($ MM): |
TESARO, Inc. Accounts Payable ($): |
TESARO, Inc. Other Current Liabilities ($ MM): |
TESARO, Inc. Total Liabilities ($ MM): |
TESARO, Inc. Stockholders Equity ($ MM): |
TESARO, Inc. Additional Paid-in Capital ($): |
TESARO, Inc. Retained Earnings ($ MM): |
TESARO, Inc. Accrued Expenses ($ MM): |
TESARO, Inc. Total Preferred Equity ($ MM): |
TESARO, Inc. Total Common Equity ($ MM): |
TESARO, Inc. Cash Flow From Operating Activities ($ MM): |
TESARO, Inc. Cash Flow From Investing Activities ($ MM): |
TESARO, Inc. Increase in Debt (Decrease) ($ MM): |
TESARO, Inc. Total Cash Flow (Net Change in Cash) ($ MM): |
Export Financials to Excel
$99 Single Company AccessInstant Full Site-Wide Access| Date | Investor | Round | Investor Type | |
| May. 2010 | View | A | Venture Capital | |
| May. 2010 | View | A | ||
| Details | Total Round A View | |||
| Jun. 2011 | View | B | Private Equity & Venture Capital | |
| Jun. 2011 | View | B | Venture Capital | |
| Jun. 2011 | View | B | Venture Capital | |
| Jun. 2011 | View | B | Venture Capital | |
| Jun. 2011 | View | B | Venture Capital | |
| Jun. 2011 | View | B | Private Equity | |
| Jun. 2011 | View | B | Corporate | |
| Jun. 2011 | View | B | Venture Capital | |
| Details | Total Round B View | |||
| Total of Funding Shown Above View | ||||
Missing a deal? Tell us about it! tips@privco.com
$99 Single Company AccessInstant Full Site-Wide Access| Date | Deal Type | Action | Resulting Status | Valuation | Amount Raised | Public Ticker | |
| Details | Jun. 2012 | View | View | View | View | View | View |
$99 Single Company AccessInstant Full Site-Wide AccessTESARO Overview
TESARO is a privately held oncology-focused biopharmaceutical company with headquarters in Waltham, MA. TESARO is set up to identify, acquire, develop and commercialize drugs for the treatment and support of cancer patients. TESARO was co-founded by former executives of MGI PHARMA, an oncology and acute-care focused Biopharmaceutical Company that Eisai Co., Ltd. acquired in 2008 for $3.9 billion.
TESARO Products
Rolapitant: a potent and long-acting neurokinin-1, or NK-1, receptor antagonist currently in Phase III clinical trials for the prevention of chemotherapy induced nausea and vomiting, or CINV.
Niraparib: formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, or PARP, inhibitor that has undergone a Phase I clinical trial in cancer patients as a monotherapy and is currently under evaluation by Merck for use in combination with temozolomide for the treatment of solid tumors. TSRO intend to evaluate niraparib for the treatment… Continue Reading →
$99 Single Company AccessInstant Full Site-Wide Access|
Get Full Access To This Report
| or | Upgrade to PrivCo Premium |
| $99 Single Company Access | Instant Full Site-Wide Access Currently 50% Off Until May. 31! |
PrivCo is the premier source for business and financial research on major privately-held companies, private market investors, and private market deals.
| Private Companies | 209,150 |
| Private Investors | 12,004 |
| Private M&A Deals | 43,155 |
| VC/Funding Rounds | 36,088 |
| Total Data Points | 95,786,176 |
PrivCo is the premier source for business and financial data on major, non-publicly traded corporations, including family owned, private equity owned, venture backed, and international unlisted companies. Click here to learn more.
PDF VERSION: Download Company Report in PDF Format
Full Online Report
